Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

平达尔 - NMPA Drug Approval Details

Approvals/NMPA/Nimodipine for Injection

Approved

化学药品

Nimodipine for Injection

海南普利制药股份有限公司🇨🇳 National Medical Products Administration

Approval Date: Feb 7, 2021
Approval ID: 7LeaeTIFdZi
Company: 海南普利制药股份有限公司
Type: 化学药品

Approval Details

Approval Id: 7LeaeTIFdZi
Approval Number: 国药准字H20051387
Generic Name: 注射用尼莫地平
Generic Name En: Nimodipine for Injection
Trade Name: 平达尔
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 2mg
Reg Date: 2021-02-07
Company Name: 海南普利制药股份有限公司
Production Company Name: 海南普利制药股份有限公司
Production Company Address: 海口市美兰区桂林洋经济开发区
Company Detail Path: /organization/hainan-poly-pharm-co-ltd
Production Company Detail Path: /organization/hainan-poly-pharm-co-ltd

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Feb 7, 2021

Approval ID

7LeaeTIFdZi

Type

化学药品

Back to NMPA Approvals